GB790521A - Improvements in or relating to antibiotics - Google Patents
Improvements in or relating to antibioticsInfo
- Publication number
- GB790521A GB790521A GB32684/55A GB3268455A GB790521A GB 790521 A GB790521 A GB 790521A GB 32684/55 A GB32684/55 A GB 32684/55A GB 3268455 A GB3268455 A GB 3268455A GB 790521 A GB790521 A GB 790521A
- Authority
- GB
- United Kingdom
- Prior art keywords
- thiactin
- per cent
- chloroform
- broad band
- shoulder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<PICT:0790521/IV (b)/1> A new antibiotic Thiactin is produced by cultivating a thiactin-producing strain of Streptomyces hawaiiensis especially S. hawaiiensis ATCC 12236 in an aqueous nutrient medium containing a source of carbohydrate, nitrogen, growth substances and mineral salts under submerged aerobic conditions at a temperature of 24 DEG to 30 DEG C. for 3 to 5 days. The initial pH of the medium is 6.0 to 6.2. Specified carbon sources are starch, sucrose, glucose, maltose, dextrose, glycerol, galactose, xylose, arabinose, rhamnose, fructose, lactose, insulin and dextrin. Specified nitrogen sources are amino acids, casein, fish meal, soybean meal, meat extracts, liver cake, urea, nitrates, ammonium compounds, distillers' grain slop, corn steep liquor, wheat steep liquor, whey, acid hydrolysed corn (or wheat) gluten, peptone, brewers' yeast, cottonseed meal, lactalbumin tryptone and offals Specified mineral salts are sodium chloride, potassium phosphate, magnesium sulphate, sodium nitrate and trace metals. A buffer such as calcium carbonate may be present. Thiactin is recovered from the clarified broth by solvent extraction and adsorption. The extraction is by means of a water-immiscible organic solvent such as butanol, chloroform or methyl isobutyl ketone. The extract is concentrated and the thiactin recovered by the addition of an alkane or by lyophilization. The crude thiactin is dissolved in a solvent used as chloroform and adsorbed on a chromatographic adsorbent such as alumina, charcoal or silica, followed by elution with e.g. methanol in chloroform. Salts of thiactin with mineral acids such as hydrochloric, phosphoric and sulphuric or organic acids such as hydrochloric, phosphoric and sulphuric or organic acids such as citric, tartaric and gluconic are prepared by adding the desired acid to an aqueous solution of thiactin. Alkali metal salts of thiactin are prepared by treating an aqueous suspension of the antibiotic with an alkali metal hydroxide. Thiactin is soluble in formamide, chloroform, 2-methoxy ethanol, butanol, dioxane, amyl alcohol; less soluble in acetone, benzene, ethyl acetate, dimethoxyethane, dimethoxy diethylene glycol and ethanol. Melts at 226-235 DEG C. Contains only the elements carbon, hydrogen, oxygen, nitrogen and sulphur and has a typical analysis of N = 15.3 to 18.1 per cent, C = 51.7 to 52.2 per cent, H = 5.56 to 5.66 per cent and S = 9.2 to 10.1 per cent. It exhibits characteristic adsorption bands in infra-red region of the spectrum when pelleted in potassium bromide at the following wavelengths expressed in microns: 2.98, 3.37; 4.20-4.28 (broad band); 6.05; 6.50-6.70 (broad band); 7.00-7.10 (shoulder) 7.25; 7.70-7.95 (broad band); 8.28; 8.85-8.98 (broad band); 9.17; 9.25-9.50 (shoulder); 9.65-9.85 (shoulder); 10.15-10.35 (broad band); 10.75; 11.23 and 12.40-12.60 (shoulder); specific rotation in chloroform of [a ]27D = - 69. On acid hydrolysis yields a mixture of amino acids comprising a -alanine, threonine, glycine, leucine and cysteine or cystine. The Rf value in (a) water is 1,2; (b) 10 per cent aqueous sodium citrate is 1; (c) butanol saturated with water is 8, 9 and 10; (d) dry methyl isobutyl ketone is 1-4; (e) butanol saturated with water containing 2 per cent p. toluene sulphonic acid is 10. Rf values in other solvent systems are also given. Thiactin is active against gram positive bacteria and mycobacteria. It is incorporated in therapeutic compositions (see Group VI).ALSO:The antibiotic thiactin (see Group IV (b)) is employed in non-toxic amounts in therapeutic compositions in admixture with a compatible carrier or diluent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB32684/55A GB790521A (en) | 1955-11-15 | 1955-11-15 | Improvements in or relating to antibiotics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB32684/55A GB790521A (en) | 1955-11-15 | 1955-11-15 | Improvements in or relating to antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
GB790521A true GB790521A (en) | 1958-02-12 |
Family
ID=10342452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB32684/55A Expired GB790521A (en) | 1955-11-15 | 1955-11-15 | Improvements in or relating to antibiotics |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB790521A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1255548A1 (en) * | 2000-01-31 | 2002-11-13 | Eisai Co., Ltd. | Use of thiostrepton as an anti-mycobacterial agent |
US10117927B2 (en) | 2015-04-28 | 2018-11-06 | Daewoong Co., Ltd. | Medium composition for preparing botulinum toxin |
-
1955
- 1955-11-15 GB GB32684/55A patent/GB790521A/en not_active Expired
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1255548A1 (en) * | 2000-01-31 | 2002-11-13 | Eisai Co., Ltd. | Use of thiostrepton as an anti-mycobacterial agent |
EP1255548A4 (en) * | 2000-01-31 | 2004-10-06 | Eisai Co Ltd | Use of thiostrepton as an anti-mycobacterial agent |
US10117927B2 (en) | 2015-04-28 | 2018-11-06 | Daewoong Co., Ltd. | Medium composition for preparing botulinum toxin |
AU2016253789B2 (en) * | 2015-04-28 | 2018-12-06 | Daewoong Co., Ltd. | Medium composition for preparing botulinum toxin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1083662A (en) | A novel antibiotic, methods for its production and therapeutic compositions containing it | |
Kobayashi et al. | Isolation and inhibitory activity of gabaculine, a new potent inhibitor of γ-aminobutyrate aminotransferase produced by a Streptomyces | |
GB2179042A (en) | Ginsenoside-Rd | |
GB715362A (en) | Improvements in or relating to antimicrobial agent | |
Nakamura et al. | A New Antibiotic, Amidinomycin [N-(2’-Amidinoethyl)-3-Aminocyclopentanecarboxamide] Produced by a Streptomyces | |
GB790521A (en) | Improvements in or relating to antibiotics | |
GB1355734A (en) | Process for producing antibiotic material | |
US2797187A (en) | Production of puromycin | |
GB764198A (en) | The antibiotic vengicide and processes for the preparation of the antibiotics oxytetracycline and vengicide | |
GB793797A (en) | Improvements in or relating to antibiotics | |
GB770065A (en) | Production of tetracycline by fermentation | |
US4353986A (en) | Process for producing antibiotic nanaomycin E | |
GB768364A (en) | A new antibiotic anisomycin | |
US3974035A (en) | Process for preparing a cephamycin type antibiotic substance | |
GB736325A (en) | Antibiotic and its production | |
GB815381A (en) | Antibiotic designated nucleocidin and preparation thereof | |
US3683074A (en) | Antibiotic selenomycin | |
US3655877A (en) | Plurallin and production thereof | |
GB684417A (en) | A new antibiotic and a process for the production thereof | |
GB830874A (en) | A new antibiotic mitomycin c and its production by fermentation | |
GB897581A (en) | Preparation of a new antibiotic aspartocin | |
GB817385A (en) | Process for the production of an antibiotic designated kanamycin | |
GB817729A (en) | A new antibiotic p.a. 371 | |
GB757089A (en) | Improvements in or relating to antibiotics | |
GB872261A (en) | New antibiotic rufochromomycine and process for its preparation |